In this study, we describe a 2-year-old boy patient with nephroblastoma who has developed toxic epidermal necrolysis (TEN) associated with the combination chemotherapy administration of dactinomycin and vincristine. A skin biopsy confirmed the diagnosis of TEN, and with methylprednisolone pulse therapy, intravenous immunoglobulin (IVIG), and supportive care, the patient improved significantly.Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, acute, and life-threatening mucocutaneous spectrum disease characterized by extensive, full-thickness epidermal necrosis and sloughing of the skin and the mucosal surface of the oral cavity, gut, kidney, eye, genitalia, and/or lung. According to the severity and extent of widespread epidermal detachment, SJS/TEN is classified as SJS, SJS/TEN overlap, and TEN with less than 10%, 10%-30%, and 30% of body surface area, respectively. The majority of cases of SJS/TEN are the results of a hypersensitive reaction to a drug, and the drugs most commonly associated with the diseases are anticonvulsants, sulfa preparations, antibiotics, nonsteroidal anti-inflammatory drugs, allopurinol and antiretroviral drugs, etc. (Chung et al., 2016). In addition to drugs, other precipitating factors include the infection-, malignancy-, collagen-, and vascular-related factors. The study of Hockett (2004) is very nonspecific regarding the types of malignancies connected with SJS and TEN, but this association may be related to the drugs used to treat specific malignancies or their side effects. In addition, there remain approximately 20% of SJS/TEN cases without an identified cause (Schwartz et al., 2013;Chung et al., 2016).A 2-year-old boy was admitted to the Department of Urological Surgery, Beijing Children's Hospital, Capital Medical University, Beijing, China, with an abdominal mass that ultrasound and computed tomography examination revealed as a left kidney nephroblastoma (size 15.8 cm×14.5 cm×12.4 cm) with pulmonary and osseous metastases, and the patient received combination chemotherapy with dactinomycin (Cosmegen; 15 μg/(kg·d) intravenously in the first 5 d) and vincristine (1.5 mg/(m 2 ·d) intravenously once per week). After one week, he developed multiple morbilliform rashes initially over limbs, then chest, with high fever, and his rash quickly progressed into a widespread confluent erythematous and necrosis eruption with blistering (Figs. 1a and 2b), painful oral erosions and conjunctivitis (Fig. 1c).The patient was clinically diagnosed as TEN by a dermatology consultation. A skin biopsy showed loss of epidermis secondary to full thickness necrosis, with mild chronic inflammation noted in the dermoepidermal junction and upper dermis (Fig. 2). These findings were consistent with TEN. Dactinomycin and vincristine were immediately discontinued and the patient was started on IVIG 1.0 g/kg body weight per day infused and methylprednisolone pulse therapy (20 mg/kg body weight) for 3 successive days. The other supportive cares included wound care, fluid and electrolyte m...